Carrion disease

Author: Dr Daniel Mazzoni, Junior Medical Officer, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia. DermNet NZ Editor-in-Chief: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. March 2019.


What is Carrion disease?

Carrion disease is a vector-borne illness caused by the bacteria Bartonella bacilliformis. It is also known as Carrión disease, Oroya fever (systemic Carrion disease) and verruga peruana (cutaneous Carrion disease) [1].

Who gets Carrion disease?

Most cases of Carrion disease occur in endemic regions of South America, due to the presence of certain sandflies that carry the causative bacteria. Carrion disease is most prevalent in areas of Peru, Ecuador and Colombia that are characterised by warm weather and low socioeconomic status [1].

B. bacilliformis is highly infectious, and those living with an infected individual have more than twice the risk of becoming infected than uninfected households [1].

Children, pregnant women, and malnourished individuals tend to be more severely affected than healthy adults [2].

What causes Carrion disease?

B. bacilliformis is a gram-negative bacterium transmitted to humans via two vector species of the sandfly, Phlebotomus verrucarum and Lutzomyia verrucarum. The mechanism of transmission is still poorly understood. Other possible routes of transmission include direct contact with infected human blood including blood transfusion, and vertical transmission between mother and child [2].

Once transmitted to a human host, B. bacilliformis invades the erythrocytes (red blood cells) and endothelial cells (interior surface of the blood vessels), resulting in a systemic and cutaneous phase respectively.

Sandflies

Lutzomyia image source (2009) PLoS Pathogens Issue Image - Vol. 5(8) August 2009. PLoS Pathog 5(8) [Public domain], via Wikimedia Commons
Phlebotomus image source http://phil.cdc.gov/PHIL_Images/20040923/a2c89591c9594e539a85b3eaee320c98/6274_lores.jpg CDC [Public domain], via Wikimedia Commons

The systemic phase

Invasion of the erythrocytes causes haemolysis and subsequently leads to the development of anaemia and systemic manifestations. The incubation period can be anywhere from three to 12 weeks following exposure to infected sandflies [3].

The cutaneous phase

Invasion of the endothelial cells induces a proliferative process that results in characteristic skin lesions. Localised angiogenesis within the lesion reduces contact between cells and impairs normal functioning. The bacteria may occupy both the inside of endothelial cells and the extracellular matrix [3–5].

What are the clinical features of Carrion disease?

Symptoms of Carrion disease can vary significantly and are often absent in patients from endemic areas. The systemic and cutaneous phases of classic Carrion disease may occur independently or sequentially. An individual can be affected in both phases [4].

Systemic Carrion disease

Oroya fever, also known as the haematic phase, is characterised by severe haemolytic anaemia and transient immunosuppression. Symptoms are non-specific and almost indistinguishable from those of other infectious diseases such as malaria and typhoid fever. Clinical features may include:

  • Low-grade fever
  • Fatigue
  • Headache
  • Jaundice
  • Pallor
  • Myalgia
  • Abdominal pain
  • Lymphadenopathy
  • Enlarged liver and spleen [1].

Cutaneous Carrion disease

Verruga peruana (Peruvian warts), the cutaneous phase of Carrion disease, is characterised by an eruption of cutaneous nodules and red-to-purple vascular lesions. It usually occurs weeks to months after the onset of the systemic phase and can persist for up to a year. This phase has very low mortality [1,4].

Lesions are polymorphic and most commonly appear on the arms and legs. They are typically painless and prone to ulceration and bleeding. Three types of cutaneous lesions may be seen.

  • Miliary lesions are small erythematous papules < 3 mm in diameter, which occasionally may be itchy. This is the most common presentation.
  • Mular lesions are erythematous round nodules > 5 mm in diameter that may extend deeper into subcutaneous tissue and muscle. They are often eroded.
  • Subdermic or nodular lesions are diffuse subcutaneous nodules that do not involve overlying skin [6,7].
Cutaneous Carrion disease

Image of verruga peruana [Public domain], via Wikimedia Commons

How is Carrion disease diagnosed?

The approach to the diagnosis of Carrion disease depends on whether the individual presents in the systemic or cutaneous phase.

The systemic phase

The diagnosis of Carrion disease in the systemic phase cannot be made on clinical features alone due to the non-specific signs and symptoms. A septic screen should be performed, and further investigations should be considered in cases if there are risk factors for Carrion disease.

The diagnosis can often be made with a Giemsa-stained peripheral blood smear. This has a low sensitivity (as has blood culture) and may not identify mild and subclinical cases. Other possible investigations include PCR, immunoblot, IgM or IgG indirect immunofluorescence, and indirect haemagglutination [8].

The cutaneous phase

The cutaneous phase of Carrion disease has characteristic skin lesions. Histopathological evaluation of a skin biopsy with Warthin-Starry silver stain or Giemsa stain may reveal bacteria.

Tissue culture of B. bacilliformis from cutaneous lesions is often unreliable due to laboratory contamination and slow growth [8].

What is the differential diagnosis for Carrion disease?

Carrion disease is often misdiagnosed because the manifestations are similar to other infectious diseases in the endemic areas.

Differential diagnoses for the systemic phase may include:

Differential diagnoses for the cutaneous phase may include:

What is the treatment for Carrion disease?

Due to the high rates of comorbid infections and conditions, multiple treatments may be needed in patients with Carrion disease [2].

Antibiotics typically used to treat Carrion disease in the systemic phase are:

  • Adults: ciprofloxacin and chloramphenicol for 14 days
  • Children: amoxicillin plus clavulanic-acid for 14 days [1].

The treatment of choice for Carrion disease in the cutaneous phase is:

  • Azithromycin as a first-line treatment
  • Erythromycin, ciprofloxacin, and rifampicin as second-line treatment [1].

What are the complications of Carrion disease?

During the immunocompromised period, an individual with systemic Carrion disease may acquire various opportunistic infections. The most common pathogens are the salmonella species [1].

If Carrion disease is acquired when pregnant, there is an increased risk of miscarriage and prematurity [2].

What is the outcome for Carrion disease?

The mortality rate in the systemic phase ranges from 40 to 85% in untreated patients. Mortality can be reduced to 10% if the infection is treated appropriately. Mortality is usually secondary to opportunistic infections or malnutrition [1].

The chronic phase of cutaneous Carrion disease is usually self-limiting and rarely results in complications.

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  1. Gomes C, Ruiz J. Carrion’s disease: the sound of silence. Clin Microbiol Rev 2017; 29: 31. DOI: 10.1128/CMR.00056-17. PubMed
  2. Pons MJ, Gomes C, del Valle-Mendoza J, et al. Carrion’s disease: more than a sand fly-vectored illness. PLos Pathog 2016; 12. DOI: 10.1371/journal.ppat.1005863. PubMed Central
  3. National Organisation of Rare Disorders. Bartonellosis. Updated 2017. Available at: https://rarediseases.org/rare-diseases/bartonellosis/ (accessed 10 February 2019).
  4. Huarcaya E, Maguina C, Torres R, et al. Bartonelosis (Carrion’s disease) in the pediatric population of Peru: an overview and update. Braz J Infect Dis 2004; 8: 331–9. PubMed
  5. Maco V, Maguina C, Tirado A, et al. Carrion’s disease (Bartonellosis bacilliformis) confirmed by histopathology in the high forest of Peru. Rev Inst Med Trop Sao Paulo 2004; 46: 171–4. PubMed
  6. Maguina C, Guerra H, Ventosilla P. Bartonellosis. Clin Dermatol 2009; 27: 271–80. DOI: 10.10.1016/j.clindermatol.2008.10.006.
  7. Ihler GM. Bartonella bacilliformis: dangerous pathogen slowly emerging from deep background. FEMS Microbiol Lett 1996; 144: 1–11. PubMed
  8. Dehio C, Maguina C, Walker DH. Tropical infectious diseases: principles, pathogens and practice (3rd edn). Bartonelloses. Elsevier, 2011.

On DermNet NZ

Books about skin diseases

See the DermNet NZ bookstore.